Yes, testosterone replacement therapy and semaglutide can be prescribed together, and many men on both medications are managing obesity-related low testosterone alongside weight loss. Semaglutide itself can raise testosterone in obese men by reducing body fat, but it also causes meaningful lean muscle loss during rapid weight loss, which is the main reason doctors are now discussing the combination. The catch is that no clinical trial has yet tested whether adding TRT actually prevents that muscle loss, so the pairing is common in practice but still unproven on that specific question.
Does Semaglutide Affect Testosterone Levels?
Semaglutide can meaningfully raise testosterone in obese men, particularly those with obesity-related functional hypogonadism. In a randomized trial of obese men with type 2 diabetes and functional hypogonadism, 24 weeks of semaglutide raised total testosterone from a baseline of 6.1 to 7.8 nmol/L, and free testosterone rose as well, with the effect driven largely by weight loss rather than a direct hormonal mechanism (Gregorič et al., Diabetes, Obesity and Metabolism, 2025). Excess body fat converts testosterone into estrogen through the enzyme aromatase, and fat also suppresses the pituitary signaling that drives testosterone production, so losing fat mass tends to lift testosterone independent of any drug given for the weight loss itself. A related 2026 review reached the same conclusion: testosterone changes during GLP-1 therapy track more closely with reduced adiposity and improved insulin resistance than with any direct action of the drug on the hypothalamic-pituitary-gonadal axis (Canal de Velasco et al., Cureus, 2026).
That means some men who start semaglutide for weight loss see their testosterone normalize on its own, without ever needing TRT. It's a good reason to recheck testosterone levels a few months into GLP-1 therapy before assuming a TRT prescription is still necessary.
Why Do Doctors Combine TRT and GLP-1 Medications for Weight Loss?
The rationale isn't about testosterone boosting weight loss, it's about protecting muscle while the GLP-1 does its job. Semaglutide produces substantial weight loss, but a meaningful share of that weight is lean tissue rather than fat. In the STEP 1 trial, semaglutide users lost about 15 percent of body weight over 68 weeks, and DEXA scans showed lean mass accounted for roughly 30 to 40 percent of the total weight lost (Canal de Velasco et al., Cureus, 2026). Other reviews put the range at 20 to 40 percent across GLP-1 trials generally (American Diabetes Association, 2025).
Testosterone has well-established anabolic effects on skeletal muscle, working through androgen receptor signaling to support protein synthesis and muscle regeneration (Canal de Velasco et al., Cureus, 2026). For a man with confirmed low testosterone who is also losing significant lean mass on a GLP-1, the logic of adding TRT to preserve muscle is mechanistically reasonable. It's also part of a broader trend in obesity medicine: at the American Diabetes Association's 2025 Scientific Sessions, researchers presented the BELIEVE trial, which paired semaglutide with a different, non-hormonal muscle-preserving drug called bimagrumab and found the combination shifted 92.8 percent of weight loss to fat mass compared with 71.8 percent on semaglutide alone (American Diabetes Association, 2025). That trial didn't use testosterone, but it shows the same clinical problem TRT is being considered for: how to keep the muscle while losing the fat.
Does TRT Actually Prevent Muscle Loss From Semaglutide?
This is the honest gap in the research. A 2026 narrative review examining exactly this question concluded that while testosterone reliably increases lean mass in men with confirmed low testosterone on its own, no trial has directly tested whether adding TRT preserves muscle specifically during GLP-1 therapy. The authors describe the idea as "mechanistically plausible yet empirically untested," and recommend it be treated as investigational rather than a proven strategy until prospective studies measure it directly with standardized testosterone thresholds and real strength outcomes, not just body scan numbers (Canal de Velasco et al., Cureus, 2026).
There's also a measurement nuance worth understanding. DEXA-based lean mass includes muscle, body water, and connective tissue, not just contractile muscle fiber, so a drop in lean mass on a body scan doesn't automatically mean a proportional loss of functional strength (Canal de Velasco et al., Cureus, 2026). Multiple reviews of GLP-1 trials note that most of the weight men lose is still fat, and that resistance training combined with adequate protein intake, generally 1.2 to 1.6 grams per kilogram of body weight daily, has the strongest evidence base for preserving lean mass and strength during rapid weight loss, stronger than any pharmacologic add-on studied so far (Poterehealth, 2025; Canal de Velasco et al., Cureus, 2026).
Professional guidelines reinforce that TRT isn't meant to be layered onto GLP-1 therapy as a general precaution. The Endocrine Society and American Urological Association both recommend testosterone replacement only for men with confirmed biochemical and clinical testosterone deficiency, not as a body-composition adjunct for men with normal testosterone who happen to be losing weight (Canal de Velasco et al., Cureus, 2026).
Is It Safe to Take TRT and Semaglutide Together?
For men who have a confirmed low testosterone diagnosis independent of the weight-loss decision, combining the two medications is generally considered manageable, but it does call for closer monitoring than either drug alone. Testosterone reliably raises red blood cell counts, and this erythropoietic effect needs regular monitoring to catch erythrocytosis before it becomes a clotting risk, a standard precaution for any man on TRT regardless of whether he's also on a GLP-1 (Canal de Velasco et al., Cureus, 2026). Semaglutide brings its own separate monitoring needs around GI tolerance, gallbladder issues, and pancreatitis risk that have nothing to do with testosterone. Because both drugs are typically weekly injections, the practical burden is mostly about staying current on two sets of labs rather than one, not a dangerous drug interaction between the two.
The more common real-world adjustment is dosing, not danger: because semaglutide-driven weight loss can itself raise testosterone by lowering aromatization, a man who started TRT at a heavier weight sometimes needs his dose reassessed a few months in, once his own natural testosterone production has partially recovered.
